Day One Biopharmaceuticals, Inc.Day One Biopharmaceuticals, Inc.Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

No trades
See on Supercharts
Market capitalization
‪1.34 B‬USD
−2.36USD
‪−188.92 M‬USD
‪58.94 M‬
Beta (1Y)
1.83

About Day One Biopharmaceuticals, Inc.

CEO
Jeremy Bender
Headquarters
Brisbane
Employees (FY)
155
Founded
2018
FIGI
BBG00V1KSN04
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of DAWN is 15.71 USD — it has decreased by 5.59% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Day One Biopharmaceuticals, Inc. stocks are traded under the ticker DAWN.
Day One Biopharmaceuticals, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
DAWN stock is 9.84% volatile and has beta coefficient of 1.83. Check out the list of the most volatile stocks — is Day One Biopharmaceuticals, Inc. there?
DAWN earnings for the last quarter are −0.54 USD per share, whereas the estimation was −0.59 USD resulting in a 7.80% surprise. The estimated earnings for the next quarter are −0.57 USD per share. See more details about Day One Biopharmaceuticals, Inc. earnings.
Yes, you can track Day One Biopharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
DAWN stock has risen by 6.58% compared to the previous week, the month change is a 0.71% rise, over the last year Day One Biopharmaceuticals, Inc. has showed a 32.57% increase.
DAWN net income for the last quarter is ‪−54.51 M‬ USD, while the quarter before that showed ‪−46.15 M‬ USD of net income which accounts for −18.12% change. Track more Day One Biopharmaceuticals, Inc. financial stats to get the full picture.
Today Day One Biopharmaceuticals, Inc. has the market capitalization of ‪1.45 B‬, it has increased by 5.27% over the last week.
No, DAWN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DAWN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Day One Biopharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
DAWN reached its all-time high on Sep 7, 2021 with the price of 28.70 USD, and its all-time low was 5.44 USD and was reached on May 27, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 24, 2024, the company has 155.00 employees. See our rating of the largest employees — is Day One Biopharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Day One Biopharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Day One Biopharmaceuticals, Inc. stock shows the buy signal. See more of Day One Biopharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Day One Biopharmaceuticals, Inc. future price: according to them, DAWN price has a max estimate of 50.00 USD and a min estimate of 10.00 USD. Read a more detailed Day One Biopharmaceuticals, Inc. forecast: see what analysts think of Day One Biopharmaceuticals, Inc. and suggest that you do with its stocks.